In patients with psoriatic arthritis on combination targeted therapy, the risk for infections is not significantly different compared with those on standard therapy.
Among adults with a diagnosis of psoriatic arthritis , those on combination targeted therapy did not have a significantly increased risk for serious bacterial infection or opportunistic infection compared with those on standard therapy.
Researchers used IBM MarketScan data from 2015 to 2024 to identify adult patients with PsA, focusing on those who received combination targeted therapy and the risk for infections in these patients. Patients on combination targeted therapy were those with 3, 4, or 6 consecutive months of overlapping medication data for two or more biologics or targeted synthetic disease-modifying antirheumatic drugs. The standard therapy cohort included patients with similar medication data for any PsA-related drug classes. Among 82,399 patients with PsA, 53,025 had at least 3 consecutive months of data for any PsA medication, with 542 receiving combination targeted therapy . The standard therapy group had 38,901 patients, and the combination therapy group had 200 patients with at least 6 months of medication data.Endpoints included all events of serious bacterial infection or opportunistic infection that resulted in hospital admission.The most common combination therapies included TNF inhibitors with apremilast and an interleukin-17 inhibitor with apremilast. In patients with PsA receiving combination targeted therapy for 3, 4, and 6 months, risks for serious infection were 7.38, 7.92, and 15.00 per 1000 patients, respectively, whereas risks for opportunistic infection were 1.85, 0, and 0 per 1000 patients, respectively. No significant difference in the risk for serious infection was found between the combination and standard therapy groups in an adjusted analysis and after propensity score matching. Similarly, the risk for opportunistic infection did not significantly differ between groups in an adjusted analysis and after propensity score matching.“ most commonly included a biologic therapy and apremilast and had a similar infection risk as standard therapy,” the authors wrote.The study was led by Alexander Wu, of the University of Texas Southwestern Medical Center in Dallas. It wasThe cohort size for combination targeted therapy was small. Most therapies included apremilast, which may not represent other combinations. Combination therapy with other immunosuppressive agents such as corticosteroids were not evaluated. The data source lacked comprehensive clinical information, potentially missing uninsured medication use.This study received partial funding support from the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network. Some authors disclosed receiving personal fees and/or grants from multiple pharmaceutical companies including Takeda, Pfizer, Novartis, UCB, and others, unrelated to this work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Arthropathic Psoriasis Psoriatic Arthropathy Psa Psoriatic Arthritis (Psa) Biologic Therapy Biologics Targeted Therapy Targeted Cancer Therapy Arthritis Joint Inflammation Opportunistic Infection Bacteria Bacterial Infection Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Corticosteroid
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Japanese Yen is pressured by a combination of factorsThe Japanese Yen (JPY) struggles to capitalize on the previous day's recovery move from over a one-week low touched against its American counterpart and drifts lower during the Asian session on Wednesday.
Read more »
Combination Therapy with Ervogastat and Clesacostat Effective for MASH Resolution but Raises Cardiovascular ConcernsThis study investigates the efficacy and safety of ervogastat and clesacostat, two novel inhibitors of de novo lipogenesis, in treating MASH and stage II or III fibrosis. While the combination therapy showed promise in resolving MASH, it was associated with a potentially unfavorable lipid profile, raising concerns about cardiovascular risks.
Read more »
Is Rivaroxaban Alone Comparable to Combination Therapy Across Age Groups in AF With Stable CADThe efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.
Read more »
Tyla's Mani-Pedi Color Combination Is Straight Out of the 2010sIt's all about balance. Tyla is welcoming a highly-debated throwback nail color trend by pairing it with a beloved summer pedicure trend.
Read more »
Cleanser for combination skin: Top 4 Perfect PicksSolve your skin puzzle! Discover the best cleanser for combination skin to balance oily T-zones & dry cheeks. Get your glow!
Read more »
Tall Boots and Culottes Are the Unexpected Combination That Actually Totally WorkDon't trust us? Just check out our outfit ideas that combine tall boots and culottes and do so flawlessly.
Read more »